Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,19202737,flow rate,"The mobile phase was acetonitrile-water containing 10 mmol/l ammonium acetate, pH 3.5 adjusted with acetic acid (75:25) at the flow rate of 1.0 ml/min.",Liquid chromatography--mass spectrometry method for the determination of gliclazide in human plasma and application to a pharmacokinetic study of gliclazide sustained release tablets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19202737/),[ml] / [min],1.0,43,DB01067,Glipizide
,19202737,Relative bioavailability,Relative bioavailability is 96.7.4 +/- 12.9%.,Liquid chromatography--mass spectrometry method for the determination of gliclazide in human plasma and application to a pharmacokinetic study of gliclazide sustained release tablets. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19202737/),%,96.7.4,44,DB01067,Glipizide
,22899546,time to reach the maximum concentration (t(max) ),"Relative to the IR formulation, the time to reach the maximum concentration (t(max) ) was delayed with the MR formulation from 1.3 to 8.7 h with the 10 mg dose and to 6.2 h with the 30 mg dose.",Comparative pharmacokinetics studies of immediate- and modified-release formulations of glipizide in pigs and dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22899546/),h,1.3,99,DB01067,Glipizide
,22899546,time to reach the maximum concentration (t(max) ),"Relative to the IR formulation, the time to reach the maximum concentration (t(max) ) was delayed with the MR formulation from 1.3 to 8.7 h with the 10 mg dose and to 6.2 h with the 30 mg dose.",Comparative pharmacokinetics studies of immediate- and modified-release formulations of glipizide in pigs and dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22899546/),h,8.7,100,DB01067,Glipizide
,22899546,time to reach the maximum concentration (t(max) ),"Relative to the IR formulation, the time to reach the maximum concentration (t(max) ) was delayed with the MR formulation from 1.3 to 8.7 h with the 10 mg dose and to 6.2 h with the 30 mg dose.",Comparative pharmacokinetics studies of immediate- and modified-release formulations of glipizide in pigs and dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22899546/),h,6.2,101,DB01067,Glipizide
,22899546,relative bioavailability (BA),The relative bioavailability (BA) was approximately 92% at 10 mg and 79% at 30 mg dose.,Comparative pharmacokinetics studies of immediate- and modified-release formulations of glipizide in pigs and dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22899546/),%,92,102,DB01067,Glipizide
,22899546,relative bioavailability (BA),The relative bioavailability (BA) was approximately 92% at 10 mg and 79% at 30 mg dose.,Comparative pharmacokinetics studies of immediate- and modified-release formulations of glipizide in pigs and dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22899546/),%,79,103,DB01067,Glipizide
,22899546,t(max),"Compared with the pigs, the 10 mg MR formulation in dogs showed a higher AUC CV of approximately 80%, a t(max) of 5.5 h, and a lower relative BA of 18%.",Comparative pharmacokinetics studies of immediate- and modified-release formulations of glipizide in pigs and dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22899546/),h,5.5,104,DB01067,Glipizide
,2693502,Tmax,"The mean values for Tmax (range 2.0-2.5 hours), Cmax (385-465 micrograms/l), and t1/2 (4.0-4.2 hours) were not significantly different in the three populations after single doses of glipizide.","Glipizide pharmacokinetics: effects of age, diabetes, and multiple dosing. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2693502/),h,2.0-2.5,6204,DB01067,Glipizide
,2693502,Cmax,"The mean values for Tmax (range 2.0-2.5 hours), Cmax (385-465 micrograms/l), and t1/2 (4.0-4.2 hours) were not significantly different in the three populations after single doses of glipizide.","Glipizide pharmacokinetics: effects of age, diabetes, and multiple dosing. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2693502/),[μg] / [l],385-465,6205,DB01067,Glipizide
,2693502,t1/2,"The mean values for Tmax (range 2.0-2.5 hours), Cmax (385-465 micrograms/l), and t1/2 (4.0-4.2 hours) were not significantly different in the three populations after single doses of glipizide.","Glipizide pharmacokinetics: effects of age, diabetes, and multiple dosing. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2693502/),h,4.0-4.2,6206,DB01067,Glipizide
,17221919,m,"The precursor-product ion combinations of m/z 130 --> 71, 446 --> 321, 206 --> 60 and 324 --> 127 were used to quantify I, II, III and IV, respectively.",Simultaneous determination of metformin and glipizide in human plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17221919/),,130,14738,DB01067,Glipizide
,7612921,limit of detection,The four sulfonylureas could be identified and measured with a precision of 5%-7% and a limit of detection close to 1-2 ng in injected external standards and 10-40 ng/ml in plasma samples.,Standardized procedure for the assay and identification of hypoglycemic sulfonylureas in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7612921/),ng,1-2,23927,DB01067,Glipizide
,7612921,limit of detection,The four sulfonylureas could be identified and measured with a precision of 5%-7% and a limit of detection close to 1-2 ng in injected external standards and 10-40 ng/ml in plasma samples.,Standardized procedure for the assay and identification of hypoglycemic sulfonylureas in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7612921/),[ng] / [ml],10-40,23928,DB01067,Glipizide
,11740344,elimination half-life,She exhibited extremely poor clearance of phenytoin with an elimination half-life of approximately 13 days.,Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11740344/),d,13,42025,DB01067,Glipizide
,8750768,total insulin response,The total insulin response was 60% greater with than without glipizide (5.9 +/- 0.6 vs 3.7 +/- 0.5 microU/ml; P < 0.001).,A novel mechanism of glipizide sulfonylurea action: decreased metabolic clearance rate of insulin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8750768/),[μu] / [ml],5.9,44585,DB01067,Glipizide
,8750768,total insulin response,The total insulin response was 60% greater with than without glipizide (5.9 +/- 0.6 vs 3.7 +/- 0.5 microU/ml; P < 0.001).,A novel mechanism of glipizide sulfonylurea action: decreased metabolic clearance rate of insulin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8750768/),[μu] / [ml],3.7,44586,DB01067,Glipizide
,8750768,total,"However, the total C-peptide responses were virtually identical (4.7 +/- 0.5 vs 4.8 +/- 0.4 nmol/l) in both studies.",A novel mechanism of glipizide sulfonylurea action: decreased metabolic clearance rate of insulin. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8750768/),[nM] / [l],4.7,44587,DB01067,Glipizide
,8750768,total,"However, the total C-peptide responses were virtually identical (4.7 +/- 0.5 vs 4.8 +/- 0.4 nmol/l) in both studies.",A novel mechanism of glipizide sulfonylurea action: decreased metabolic clearance rate of insulin. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8750768/),[nM] / [l],4.8,44588,DB01067,Glipizide
,8750768,responses,"However, the total C-peptide responses were virtually identical (4.7 +/- 0.5 vs 4.8 +/- 0.4 nmol/l) in both studies.",A novel mechanism of glipizide sulfonylurea action: decreased metabolic clearance rate of insulin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8750768/),[nM] / [l],4.7,44589,DB01067,Glipizide
,8750768,responses,"However, the total C-peptide responses were virtually identical (4.7 +/- 0.5 vs 4.8 +/- 0.4 nmol/l) in both studies.",A novel mechanism of glipizide sulfonylurea action: decreased metabolic clearance rate of insulin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8750768/),[nM] / [l],4.8,44590,DB01067,Glipizide
,8750768,steady-state plasma insulin concentration,"The steady-state plasma insulin concentration during the 4th h, i.e., 1-2 h after glipizide ingestion, was significantly higher than during the 2nd h, i.e., before glipizide ingestion (99 +/- 22 vs 78 +/- 17 microU/ml; P < 0.01).",A novel mechanism of glipizide sulfonylurea action: decreased metabolic clearance rate of insulin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8750768/),[μu] / [ml],99,44591,DB01067,Glipizide
,8750768,steady-state plasma insulin concentration,"The steady-state plasma insulin concentration during the 4th h, i.e., 1-2 h after glipizide ingestion, was significantly higher than during the 2nd h, i.e., before glipizide ingestion (99 +/- 22 vs 78 +/- 17 microU/ml; P < 0.01).",A novel mechanism of glipizide sulfonylurea action: decreased metabolic clearance rate of insulin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8750768/),[μu] / [ml],78,44592,DB01067,Glipizide
,8750768,glucose uptake,"In addition, glucose uptake during the 4th h was greater (8.0 +/- 1.6 vs 6.4 +/- 1.5 mg/kg.min) and the MCR of insulin was reduced (503 +/- 126 vs 621 +/- 176 ml/m2.min; P < 0.01).",A novel mechanism of glipizide sulfonylurea action: decreased metabolic clearance rate of insulin. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8750768/),[mg] / [kg·min],8.0,44593,DB01067,Glipizide
,8750768,glucose uptake,"In addition, glucose uptake during the 4th h was greater (8.0 +/- 1.6 vs 6.4 +/- 1.5 mg/kg.min) and the MCR of insulin was reduced (503 +/- 126 vs 621 +/- 176 ml/m2.min; P < 0.01).",A novel mechanism of glipizide sulfonylurea action: decreased metabolic clearance rate of insulin. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8750768/),[mg] / [kg·min],6.4,44594,DB01067,Glipizide
,8750768,MCR,"In addition, glucose uptake during the 4th h was greater (8.0 +/- 1.6 vs 6.4 +/- 1.5 mg/kg.min) and the MCR of insulin was reduced (503 +/- 126 vs 621 +/- 176 ml/m2.min; P < 0.01).",A novel mechanism of glipizide sulfonylurea action: decreased metabolic clearance rate of insulin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8750768/),[ml] / [m2·min],503,44595,DB01067,Glipizide
,8750768,MCR,"In addition, glucose uptake during the 4th h was greater (8.0 +/- 1.6 vs 6.4 +/- 1.5 mg/kg.min) and the MCR of insulin was reduced (503 +/- 126 vs 621 +/- 176 ml/m2.min; P < 0.01).",A novel mechanism of glipizide sulfonylurea action: decreased metabolic clearance rate of insulin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8750768/),[ml] / [m2·min],621,44596,DB01067,Glipizide
,8888072,terminal elimination half-lives,"The mean +/- SD terminal elimination half-lives were 9.67 +/- 5.6 and 9.35 +/- 4.6 hours after a single dose and 12 weeks, respectively.",The influence of multiple dosing and age on the pharmacokinetics and pharmacodynamics of glipizide in patients with type II diabetes mellitus. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8888072/),h,9.67,45030,DB01067,Glipizide
,8888072,terminal elimination half-lives,"The mean +/- SD terminal elimination half-lives were 9.67 +/- 5.6 and 9.35 +/- 4.6 hours after a single dose and 12 weeks, respectively.",The influence of multiple dosing and age on the pharmacokinetics and pharmacodynamics of glipizide in patients with type II diabetes mellitus. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8888072/),h,9.35,45031,DB01067,Glipizide
,8888072,Fast,Fasting plasma glucose concentrations decreased from 12.3 +/- 3.6 mmol/L before the first dose of glipizide to 9.2 +/- 1.7 mmol/L after 12 weeks of treatment.,The influence of multiple dosing and age on the pharmacokinetics and pharmacodynamics of glipizide in patients with type II diabetes mellitus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8888072/),[mM] / [l],12.3,45032,DB01067,Glipizide
,8888072,Fast,Fasting plasma glucose concentrations decreased from 12.3 +/- 3.6 mmol/L before the first dose of glipizide to 9.2 +/- 1.7 mmol/L after 12 weeks of treatment.,The influence of multiple dosing and age on the pharmacokinetics and pharmacodynamics of glipizide in patients with type II diabetes mellitus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8888072/),,9.,45033,DB01067,Glipizide
,8888072,area under the serum concentration-time curve from zero to 4 hours for glucose (AUC0-4.glucose),"The values for area under the serum concentration-time curve from zero to 4 hours for glucose (AUC0-4.glucose) were significantly reduced at week 12 (baseline 49.8 +/- 15.6, week 12 37.8 +/- 9.8 mmol/L/hr).",The influence of multiple dosing and age on the pharmacokinetics and pharmacodynamics of glipizide in patients with type II diabetes mellitus. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8888072/),[mM] / [h·l],49.8,45034,DB01067,Glipizide
,8888072,area under the serum concentration-time curve from zero to 4 hours for glucose (AUC0-4.glucose),"The values for area under the serum concentration-time curve from zero to 4 hours for glucose (AUC0-4.glucose) were significantly reduced at week 12 (baseline 49.8 +/- 15.6, week 12 37.8 +/- 9.8 mmol/L/hr).",The influence of multiple dosing and age on the pharmacokinetics and pharmacodynamics of glipizide in patients with type II diabetes mellitus. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8888072/),[mM] / [h·l],37.8,45035,DB01067,Glipizide
,8888072,AUC0-4.,"Glipizide provoked an increase in serum insulin and C-peptide concentrations (AUC0-4.insulin: baseline 698 +/- 327, single dose 954 +/- 461, long-term dosing 945 +/- 600 pmol/L/hr).",The influence of multiple dosing and age on the pharmacokinetics and pharmacodynamics of glipizide in patients with type II diabetes mellitus. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8888072/),[pM] / [h·l],698,45036,DB01067,Glipizide
,8888072,AUC0-4.,"Glipizide provoked an increase in serum insulin and C-peptide concentrations (AUC0-4.insulin: baseline 698 +/- 327, single dose 954 +/- 461, long-term dosing 945 +/- 600 pmol/L/hr).",The influence of multiple dosing and age on the pharmacokinetics and pharmacodynamics of glipizide in patients with type II diabetes mellitus. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8888072/),[pM] / [h·l],954,45037,DB01067,Glipizide
,8888072,AUC0-4.,"Glipizide provoked an increase in serum insulin and C-peptide concentrations (AUC0-4.insulin: baseline 698 +/- 327, single dose 954 +/- 461, long-term dosing 945 +/- 600 pmol/L/hr).",The influence of multiple dosing and age on the pharmacokinetics and pharmacodynamics of glipizide in patients with type II diabetes mellitus. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8888072/),[pM] / [h·l],945,45038,DB01067,Glipizide
,6765225,plasma half-life,"On both days, the drug peaked within 1.2-1.8 h and displayed a plasma half-life of between 2.5 and 3.2 h.",Bioavailability of glipizide and its effect on blood glucose and insulin levels in patients with non-insulin-dependent diabetes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6765225/),h,2.5 and 3.2,55990,DB01067,Glipizide
,7116738,distribution volume,"The distribution volume at assumed distribution equilibrium was small (10L), and the elimination half-life was short (2 to 4 hours).","Bioavailability, pharmacokinetics and effects of glipizide in type 2 diabetics. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7116738/),l,10,57131,DB01067,Glipizide
,7116738,elimination half-life,"The distribution volume at assumed distribution equilibrium was small (10L), and the elimination half-life was short (2 to 4 hours).","Bioavailability, pharmacokinetics and effects of glipizide in type 2 diabetics. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7116738/),h,2 to 4,57132,DB01067,Glipizide
,7116738,Gastrointestinal bioavailability,Gastrointestinal bioavailability was 100%.,"Bioavailability, pharmacokinetics and effects of glipizide in type 2 diabetics. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7116738/),%,100,57133,DB01067,Glipizide
,30398126,Tmax,AZI (500 mg/kg) pretreatment significantly decreased AUC and increased Tmax to 8 h.,Effect of Aqueous Extract of Azadirachta indica Leaves on Pharmacokineics and Pharmacodynamics of Glipizide. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30398126/),h,8,63853,DB01067,Glipizide
,11406737,elimination half-life,The elimination half-life of glyburide was shortened from 2.0 to 1.7 hours (P <.05) by rifampin.,Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11406737/),h,2.0,69073,DB01067,Glipizide
,11406737,elimination half-life,The elimination half-life of glyburide was shortened from 2.0 to 1.7 hours (P <.05) by rifampin.,Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11406737/),h,1.7,69074,DB01067,Glipizide
,11406737,half-life,"In study II, rifampin decreased the AUC(0-infinity) of glipizide by 22% (P <.05) and shortened its half-life from 3.0 to 1.9 hours (P =.01).",Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11406737/),h,3.0,69075,DB01067,Glipizide
,11406737,half-life,"In study II, rifampin decreased the AUC(0-infinity) of glipizide by 22% (P <.05) and shortened its half-life from 3.0 to 1.9 hours (P =.01).",Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11406737/),h,1.9,69076,DB01067,Glipizide
,27650591,mass transition ion pairs (m/z),"The optimized mass transition ion pairs (m/z) were 318.1 → 274.0 for EPA, 415.1 → 266.9 for PUE and 444.2 → 166.9 for IS.",Simultaneous determination of epalrestat and puerarin in rat plasma by UHPLC-MS/MS: Application to their pharmacokinetic interaction study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27650591/),,318.1,69740,DB01067,Glipizide
,27650591,mass transition ion pairs (m/z),"The optimized mass transition ion pairs (m/z) were 318.1 → 274.0 for EPA, 415.1 → 266.9 for PUE and 444.2 → 166.9 for IS.",Simultaneous determination of epalrestat and puerarin in rat plasma by UHPLC-MS/MS: Application to their pharmacokinetic interaction study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27650591/),,274.0,69741,DB01067,Glipizide
,27650591,mass transition ion pairs (m/z),"The optimized mass transition ion pairs (m/z) were 318.1 → 274.0 for EPA, 415.1 → 266.9 for PUE and 444.2 → 166.9 for IS.",Simultaneous determination of epalrestat and puerarin in rat plasma by UHPLC-MS/MS: Application to their pharmacokinetic interaction study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27650591/),,415.1,69742,DB01067,Glipizide
,27650591,mass transition ion pairs (m/z),"The optimized mass transition ion pairs (m/z) were 318.1 → 274.0 for EPA, 415.1 → 266.9 for PUE and 444.2 → 166.9 for IS.",Simultaneous determination of epalrestat and puerarin in rat plasma by UHPLC-MS/MS: Application to their pharmacokinetic interaction study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27650591/),,266.9,69743,DB01067,Glipizide
,27650591,mass transition ion pairs (m/z),"The optimized mass transition ion pairs (m/z) were 318.1 → 274.0 for EPA, 415.1 → 266.9 for PUE and 444.2 → 166.9 for IS.",Simultaneous determination of epalrestat and puerarin in rat plasma by UHPLC-MS/MS: Application to their pharmacokinetic interaction study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27650591/),,444.2,69744,DB01067,Glipizide
,27650591,mass transition ion pairs (m/z),"The optimized mass transition ion pairs (m/z) were 318.1 → 274.0 for EPA, 415.1 → 266.9 for PUE and 444.2 → 166.9 for IS.",Simultaneous determination of epalrestat and puerarin in rat plasma by UHPLC-MS/MS: Application to their pharmacokinetic interaction study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27650591/),,166.9,69745,DB01067,Glipizide
,28284082,m/z,"The ion transitions of the precursor to the product ion were principally protonated ions [M+H]+ at m/z 446.4→m/z 321.1 for glipizide, m/z 462.2→m/z 321.1 for the four hydroxylated forms of glipizide, m/z 287.2→m/z 188.0 for 4'-OH-tolbutamide, and m/z 324.1→m/z 127.1 for gliclazide.",Simultaneous determination of glipizide and its four hydroxylated metabolites in human urine using LC-MS/MS and its application in urinary phenotype study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28284082/),→,287.2,73622,DB01067,Glipizide
,28284082,m/z,"The ion transitions of the precursor to the product ion were principally protonated ions [M+H]+ at m/z 446.4→m/z 321.1 for glipizide, m/z 462.2→m/z 321.1 for the four hydroxylated forms of glipizide, m/z 287.2→m/z 188.0 for 4'-OH-tolbutamide, and m/z 324.1→m/z 127.1 for gliclazide.",Simultaneous determination of glipizide and its four hydroxylated metabolites in human urine using LC-MS/MS and its application in urinary phenotype study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28284082/),,188.0,73623,DB01067,Glipizide
,28284082,m,"The ion transitions of the precursor to the product ion were principally protonated ions [M+H]+ at m/z 446.4→m/z 321.1 for glipizide, m/z 462.2→m/z 321.1 for the four hydroxylated forms of glipizide, m/z 287.2→m/z 188.0 for 4'-OH-tolbutamide, and m/z 324.1→m/z 127.1 for gliclazide.",Simultaneous determination of glipizide and its four hydroxylated metabolites in human urine using LC-MS/MS and its application in urinary phenotype study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28284082/),→,324.1,73624,DB01067,Glipizide
,1646724,AUC,"Sodium bicarbonate significantly increased the AUC of plasma glipizide from 0 to 0.5 h, 0 to 1 h, and from 0 to 2 h (six-, four- and twofold, respectively).",Differential effects of sodium bicarbonate and aluminium hydroxide on the absorption and activity of glipizide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1646724/),h,0,99733,DB01067,Glipizide
,1646724,time to peak concentration (tmax),The time to peak concentration (tmax) fell from 2.5 h during the control phase to 1.0 h during the sodium bicarbonate phase.,Differential effects of sodium bicarbonate and aluminium hydroxide on the absorption and activity of glipizide. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1646724/),h,2.5,99734,DB01067,Glipizide
,1646724,time to peak concentration (tmax),The time to peak concentration (tmax) fell from 2.5 h during the control phase to 1.0 h during the sodium bicarbonate phase.,Differential effects of sodium bicarbonate and aluminium hydroxide on the absorption and activity of glipizide. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1646724/),h,1.0,99735,DB01067,Glipizide
,24418334,flow rate,Elute was monitored at 230 nm with a flow rate of 1 mL/min.,Development and validation of RP-HPLC method for quantification of glipizide in biological macromolecules. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24418334/),[ml] / [min],1,122542,DB01067,Glipizide
,24418334,Retention times,Retention times of GPZ and internal standard (gliclazide) were 7.32 and 9.02 min respectively.,Development and validation of RP-HPLC method for quantification of glipizide in biological macromolecules. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24418334/),min,7.32,122543,DB01067,Glipizide
,24418334,Retention times,Retention times of GPZ and internal standard (gliclazide) were 7.32 and 9.02 min respectively.,Development and validation of RP-HPLC method for quantification of glipizide in biological macromolecules. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24418334/),min,9.02,122544,DB01067,Glipizide
,24418334,Maximum plasma drug concentration,"Maximum plasma drug concentration, area under the plasma drug concentration-time curve and elimination half life for GPZ floating microspheres were 2.88±0.29 μg mL(-1), 38.46±2.26 μg h mL(-1) and 13.55±1.36 h respectively.",Development and validation of RP-HPLC method for quantification of glipizide in biological macromolecules. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24418334/),[μg] / [ml],2.88,122545,DB01067,Glipizide
,24418334,area under the plasma drug concentration-time curve,"Maximum plasma drug concentration, area under the plasma drug concentration-time curve and elimination half life for GPZ floating microspheres were 2.88±0.29 μg mL(-1), 38.46±2.26 μg h mL(-1) and 13.55±1.36 h respectively.",Development and validation of RP-HPLC method for quantification of glipizide in biological macromolecules. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24418334/),[h·μg] / [ml],38.46,122546,DB01067,Glipizide
,24418334,elimination half life,"Maximum plasma drug concentration, area under the plasma drug concentration-time curve and elimination half life for GPZ floating microspheres were 2.88±0.29 μg mL(-1), 38.46±2.26 μg h mL(-1) and 13.55±1.36 h respectively.",Development and validation of RP-HPLC method for quantification of glipizide in biological macromolecules. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24418334/),h,13.55,122547,DB01067,Glipizide
,6341263,volume of the central compartment,The volume of the central compartment was 4.25 +/- 0.25 l and the steady-state volume of distribution averaged 11.7 +/- 1.1 l.,Pharmacokinetics and pharmacodynamics of glipizide in healthy volunteers. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6341263/),l,4.25,123400,DB01067,Glipizide
,6341263,steady-state volume of distribution,The volume of the central compartment was 4.25 +/- 0.25 l and the steady-state volume of distribution averaged 11.7 +/- 1.1 l.,Pharmacokinetics and pharmacodynamics of glipizide in healthy volunteers. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6341263/),l,11.7,123401,DB01067,Glipizide
,6341263,half-life of g,The half-life of glipizide elimination averaged 3.3 h both after i.v. and p.o. administration.,Pharmacokinetics and pharmacodynamics of glipizide in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6341263/),h,3.3,123402,DB01067,Glipizide
,6341263,total plasma clearance,"The total plasma clearance of glipizide was 42.2 +/- 5.4 ml/min, whereas that of protein unbound fraction was 1350 +/- 130 ml/min.",Pharmacokinetics and pharmacodynamics of glipizide in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6341263/),[ml] / [min],42.2,123403,DB01067,Glipizide
,6341263,protein unbound fraction,"The total plasma clearance of glipizide was 42.2 +/- 5.4 ml/min, whereas that of protein unbound fraction was 1350 +/- 130 ml/min.",Pharmacokinetics and pharmacodynamics of glipizide in healthy volunteers. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6341263/),[ml] / [min],1350,123404,DB01067,Glipizide
,7479199,area under the curve from time zero to infinity,"The mean values for area under the curve from time zero to infinity (range 7240.7-10,001.8 micrograms.L-1.hr-1; 16,226-22,414 nmol.L-1.hr-1), clearance (0.44-0.64 ml.min-1.kg-1; 0.07-0.11 ml.sec-1.kg-1), post-distribution phase volume (0.17-0.25 L.kg-1), and half-life (4.2-5.4 hrs) were not significantly different among regimens.",Pharmacokinetics and pharmacodynamics of glipizide after once-daily and divided doses. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7479199/),[μg] / [h·l],"7240.7-10,001.8",125842,DB01067,Glipizide
,7479199,area under the curve from time zero to infinity,"The mean values for area under the curve from time zero to infinity (range 7240.7-10,001.8 micrograms.L-1.hr-1; 16,226-22,414 nmol.L-1.hr-1), clearance (0.44-0.64 ml.min-1.kg-1; 0.07-0.11 ml.sec-1.kg-1), post-distribution phase volume (0.17-0.25 L.kg-1), and half-life (4.2-5.4 hrs) were not significantly different among regimens.",Pharmacokinetics and pharmacodynamics of glipizide after once-daily and divided doses. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7479199/),[nM] / [h·l],"16,226-22,414",125843,DB01067,Glipizide
,7479199,clearance,"The mean values for area under the curve from time zero to infinity (range 7240.7-10,001.8 micrograms.L-1.hr-1; 16,226-22,414 nmol.L-1.hr-1), clearance (0.44-0.64 ml.min-1.kg-1; 0.07-0.11 ml.sec-1.kg-1), post-distribution phase volume (0.17-0.25 L.kg-1), and half-life (4.2-5.4 hrs) were not significantly different among regimens.",Pharmacokinetics and pharmacodynamics of glipizide after once-daily and divided doses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7479199/),[ml] / [kg·min],0.44-0.64,125844,DB01067,Glipizide
,7479199,clearance,"The mean values for area under the curve from time zero to infinity (range 7240.7-10,001.8 micrograms.L-1.hr-1; 16,226-22,414 nmol.L-1.hr-1), clearance (0.44-0.64 ml.min-1.kg-1; 0.07-0.11 ml.sec-1.kg-1), post-distribution phase volume (0.17-0.25 L.kg-1), and half-life (4.2-5.4 hrs) were not significantly different among regimens.",Pharmacokinetics and pharmacodynamics of glipizide after once-daily and divided doses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7479199/),[ml] / [kg·s],0.07-0.11,125845,DB01067,Glipizide
,7479199,post-distribution phase volume,"The mean values for area under the curve from time zero to infinity (range 7240.7-10,001.8 micrograms.L-1.hr-1; 16,226-22,414 nmol.L-1.hr-1), clearance (0.44-0.64 ml.min-1.kg-1; 0.07-0.11 ml.sec-1.kg-1), post-distribution phase volume (0.17-0.25 L.kg-1), and half-life (4.2-5.4 hrs) were not significantly different among regimens.",Pharmacokinetics and pharmacodynamics of glipizide after once-daily and divided doses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7479199/),[l] / [kg],0.17-0.25,125846,DB01067,Glipizide
,7479199,half-life,"The mean values for area under the curve from time zero to infinity (range 7240.7-10,001.8 micrograms.L-1.hr-1; 16,226-22,414 nmol.L-1.hr-1), clearance (0.44-0.64 ml.min-1.kg-1; 0.07-0.11 ml.sec-1.kg-1), post-distribution phase volume (0.17-0.25 L.kg-1), and half-life (4.2-5.4 hrs) were not significantly different among regimens.",Pharmacokinetics and pharmacodynamics of glipizide after once-daily and divided doses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7479199/),h,4.2-5.4,125847,DB01067,Glipizide
,22763773,flow rate,"After one-step protein precipitation of 200 μL plasma with methanol, metformin, glipizide and IS were separated on a Kromasil Phenyl column (4.6 × 150 mm, 5 µm) at 40°C with an isocratic mobile phase consisting of methanol-10 mmol/L ammonium acetate (75:25, v/v) at a flow rate of 0.35 mL/min.",Simultaneous quantification of metformin and glipizide in human plasma by high-performance liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22763773/),[ml] / [min],0.35,129770,DB01067,Glipizide
,30856604,flow rate,"The chromatographic separation was operated on an economical Hanbon ODS-2 C18 column (150 mm × 2.1 mm, 10 μm) with isocratic elution using 10 mM ammonium acetate containing 0.01% formic acid and acetonitrile (72:28, v/v) as the mobile phase at the flow rate of 0.5 mL/min.",Development and validation of a specific and sensitive LC-MS/MS method for determination of eslicarbazepine in human plasma and its clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30856604/),[ml] / [min],0.5,130632,DB01067,Glipizide
,19629959,total chroma,"The total chromatographic runtime was approximately 3.0 min with retention time for fexofenadine and IS at approximately 1.9 and 2.1 min, respectively.",Measurement of fexofenadine concentration in micro-sample human plasma by a rapid and sensitive LC-MS/MS employing protein precipitation: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19629959/),min,3.0,133935,DB01067,Glipizide
,19629959,retention time,"The total chromatographic runtime was approximately 3.0 min with retention time for fexofenadine and IS at approximately 1.9 and 2.1 min, respectively.",Measurement of fexofenadine concentration in micro-sample human plasma by a rapid and sensitive LC-MS/MS employing protein precipitation: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19629959/),min,1.9,133936,DB01067,Glipizide
,19629959,retention time,"The total chromatographic runtime was approximately 3.0 min with retention time for fexofenadine and IS at approximately 1.9 and 2.1 min, respectively.",Measurement of fexofenadine concentration in micro-sample human plasma by a rapid and sensitive LC-MS/MS employing protein precipitation: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19629959/),min,2.1,133937,DB01067,Glipizide
,15900936,transdermal absorption,Mean +/- SD transdermal absorption was 20 +/- 14% of oral absorption.,Evaluation of transdermal application of glipizide in a pluronic lecithin gel to healthy cats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15900936/),%,20,139037,DB01067,Glipizide
,15900936,Elimination half-life,Elimination half-life was variable (16.8 +/- 12 hours orally and 15.5 +/- 15.3 hours transdermally).,Evaluation of transdermal application of glipizide in a pluronic lecithin gel to healthy cats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15900936/),h,16.8,139038,DB01067,Glipizide
,15900936,Elimination half-life,Elimination half-life was variable (16.8 +/- 12 hours orally and 15.5 +/- 15.3 hours transdermally).,Evaluation of transdermal application of glipizide in a pluronic lecithin gel to healthy cats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15900936/),h,15.5,139039,DB01067,Glipizide
<,9463023,action period,"The action period for ""short-term"" sulfonamides is < or = 24 h (tolbutamide, glipizide) and can exceed 24 h for ""long-term"" sulfonamides (e.g. glibenclamide).","[Pharmacokinetics of hypoglycemic sulfonamides: Ozidia, a new concept]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9463023/),h,24,140609,DB01067,Glipizide
exceed,9463023,action period,"The action period for ""short-term"" sulfonamides is < or = 24 h (tolbutamide, glipizide) and can exceed 24 h for ""long-term"" sulfonamides (e.g. glibenclamide).","[Pharmacokinetics of hypoglycemic sulfonamides: Ozidia, a new concept]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9463023/),h,24,140610,DB01067,Glipizide
,26446475,half-life,"The half-life of glipizide did not change, and reached 3.8±0.7 and 3.7±1.8 h in the MODY and control subjects, respectively.",Half-Life of Sulfonylureas in HNF1A and HNF4A Human MODY Patients is not Prolonged as Suggested by the Mouse Hnf1a(-/-) Model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26446475/),h,3.8,146051,DB01067,Glipizide
,26446475,half-life,"The half-life of glipizide did not change, and reached 3.8±0.7 and 3.7±1.8 h in the MODY and control subjects, respectively.",Half-Life of Sulfonylureas in HNF1A and HNF4A Human MODY Patients is not Prolonged as Suggested by the Mouse Hnf1a(-/-) Model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26446475/),h,3.7,146052,DB01067,Glipizide
,26446475,t1/2,"The half-life of glibenclamide was increased only in some MODY subjects (t1/2 9.5±6.7 and 5.0±1.4 h, respectively).",Half-Life of Sulfonylureas in HNF1A and HNF4A Human MODY Patients is not Prolonged as Suggested by the Mouse Hnf1a(-/-) Model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26446475/),h,9.5,146053,DB01067,Glipizide
,26446475,t1/2,"The half-life of glibenclamide was increased only in some MODY subjects (t1/2 9.5±6.7 and 5.0±1.4 h, respectively).",Half-Life of Sulfonylureas in HNF1A and HNF4A Human MODY Patients is not Prolonged as Suggested by the Mouse Hnf1a(-/-) Model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26446475/),h,5.0,146054,DB01067,Glipizide
,9850449,trough CsA concentration,"Whole blood trough CsA concentration was not altered by glipizide treatment, 256 +/- 76 micrograms/L off and 242 +/- 73 micrograms/L (mean +/- SD) with glipizide coadministration.",Glipizide treatment of post-transplant diabetes does not interfere with cyclosporine pharmacokinetics in renal allograft recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9850449/),[μg] / [l],256,171804,DB01067,Glipizide
,9850449,trough CsA concentration,"Whole blood trough CsA concentration was not altered by glipizide treatment, 256 +/- 76 micrograms/L off and 242 +/- 73 micrograms/L (mean +/- SD) with glipizide coadministration.",Glipizide treatment of post-transplant diabetes does not interfere with cyclosporine pharmacokinetics in renal allograft recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9850449/),[μg] / [l],242,171805,DB01067,Glipizide
,9850449,area under the curve (AUC),"The area under the curve (AUC) and terminal half-life of CsA remained unchanged with glipizide treatment: 6391 +/- 1483 micrograms/L per h and 7.3 +/- 1.5 h without; and 6279 +/- 1601 micrograms/L per h and 7.1 +/- 1.8 h with glipizide, respectively.",Glipizide treatment of post-transplant diabetes does not interfere with cyclosporine pharmacokinetics in renal allograft recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9850449/),[μg] / [h·l],6391,171806,DB01067,Glipizide
,9850449,area under the curve (AUC),"The area under the curve (AUC) and terminal half-life of CsA remained unchanged with glipizide treatment: 6391 +/- 1483 micrograms/L per h and 7.3 +/- 1.5 h without; and 6279 +/- 1601 micrograms/L per h and 7.1 +/- 1.8 h with glipizide, respectively.",Glipizide treatment of post-transplant diabetes does not interfere with cyclosporine pharmacokinetics in renal allograft recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9850449/),[μg] / [h·l],6279,171807,DB01067,Glipizide
,9850449,terminal half-life,"The area under the curve (AUC) and terminal half-life of CsA remained unchanged with glipizide treatment: 6391 +/- 1483 micrograms/L per h and 7.3 +/- 1.5 h without; and 6279 +/- 1601 micrograms/L per h and 7.1 +/- 1.8 h with glipizide, respectively.",Glipizide treatment of post-transplant diabetes does not interfere with cyclosporine pharmacokinetics in renal allograft recipients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9850449/),h,7.3,171808,DB01067,Glipizide
,9850449,terminal half-life,"The area under the curve (AUC) and terminal half-life of CsA remained unchanged with glipizide treatment: 6391 +/- 1483 micrograms/L per h and 7.3 +/- 1.5 h without; and 6279 +/- 1601 micrograms/L per h and 7.1 +/- 1.8 h with glipizide, respectively.",Glipizide treatment of post-transplant diabetes does not interfere with cyclosporine pharmacokinetics in renal allograft recipients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9850449/),h,7.1,171809,DB01067,Glipizide
,9850449,peak concentration (Cmax),No change in the CsA peak concentration (Cmax) was observed: 1507 +/- 406 micrograms/L without and 1469 +/- 538 micrograms/L with glipizide coadministration.,Glipizide treatment of post-transplant diabetes does not interfere with cyclosporine pharmacokinetics in renal allograft recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9850449/),[μg] / [l],1507,171810,DB01067,Glipizide
,9850449,peak concentration (Cmax),No change in the CsA peak concentration (Cmax) was observed: 1507 +/- 406 micrograms/L without and 1469 +/- 538 micrograms/L with glipizide coadministration.,Glipizide treatment of post-transplant diabetes does not interfere with cyclosporine pharmacokinetics in renal allograft recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9850449/),[μg] / [l],1469,171811,DB01067,Glipizide
,23278689,solubility,The solubility of GPZ in phosphate buffer pH 6.8 was greater for MW-SD (72.250 ± 0.154 μg/ml) than CH-SD (46 ± 0.201 μg/ml).,Microwave-induced solid dispersion technology to improve bioavailability of glipizide. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23278689/),[μg] / [ml],72.250,180250,DB01067,Glipizide
,23278689,solubility,The solubility of GPZ in phosphate buffer pH 6.8 was greater for MW-SD (72.250 ± 0.154 μg/ml) than CH-SD (46 ± 0.201 μg/ml).,Microwave-induced solid dispersion technology to improve bioavailability of glipizide. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23278689/),[μg] / [ml],46,180251,DB01067,Glipizide
,23278689,relative bioavailability,In-vivo pharmacokinetic study in rabbits revealed that the relative bioavailability of GPZ from MW-SD tablets improved greatly (153.73 ± 9.713%).,Microwave-induced solid dispersion technology to improve bioavailability of glipizide. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23278689/),%,153.73,180252,DB01067,Glipizide
,3356119,time to peak concentration,"The mean values for young and older subjects for time to peak concentration (2.1 versus 2.5 hours), peak concentrations (465 versus 399 micrograms/mL), elimination half-life (4.2 versus 4.0 hours), clearance (38.8 versus 38.1 mL/min), and distribution volume at steady state (12.5 versus 14.3 L) were not significant.",Glipizide pharmacokinetics in young and elderly volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3356119/),h,2.1,188329,DB01067,Glipizide
,3356119,time to peak concentration,"The mean values for young and older subjects for time to peak concentration (2.1 versus 2.5 hours), peak concentrations (465 versus 399 micrograms/mL), elimination half-life (4.2 versus 4.0 hours), clearance (38.8 versus 38.1 mL/min), and distribution volume at steady state (12.5 versus 14.3 L) were not significant.",Glipizide pharmacokinetics in young and elderly volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3356119/),h,2.5,188330,DB01067,Glipizide
,3356119,peak concentrations,"The mean values for young and older subjects for time to peak concentration (2.1 versus 2.5 hours), peak concentrations (465 versus 399 micrograms/mL), elimination half-life (4.2 versus 4.0 hours), clearance (38.8 versus 38.1 mL/min), and distribution volume at steady state (12.5 versus 14.3 L) were not significant.",Glipizide pharmacokinetics in young and elderly volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3356119/),[μg] / [ml],465,188331,DB01067,Glipizide
,3356119,peak concentrations,"The mean values for young and older subjects for time to peak concentration (2.1 versus 2.5 hours), peak concentrations (465 versus 399 micrograms/mL), elimination half-life (4.2 versus 4.0 hours), clearance (38.8 versus 38.1 mL/min), and distribution volume at steady state (12.5 versus 14.3 L) were not significant.",Glipizide pharmacokinetics in young and elderly volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3356119/),[μg] / [ml],399,188332,DB01067,Glipizide
,3356119,elimination half-life,"The mean values for young and older subjects for time to peak concentration (2.1 versus 2.5 hours), peak concentrations (465 versus 399 micrograms/mL), elimination half-life (4.2 versus 4.0 hours), clearance (38.8 versus 38.1 mL/min), and distribution volume at steady state (12.5 versus 14.3 L) were not significant.",Glipizide pharmacokinetics in young and elderly volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3356119/),h,4.2,188333,DB01067,Glipizide
,3356119,elimination half-life,"The mean values for young and older subjects for time to peak concentration (2.1 versus 2.5 hours), peak concentrations (465 versus 399 micrograms/mL), elimination half-life (4.2 versus 4.0 hours), clearance (38.8 versus 38.1 mL/min), and distribution volume at steady state (12.5 versus 14.3 L) were not significant.",Glipizide pharmacokinetics in young and elderly volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3356119/),h,4.0,188334,DB01067,Glipizide
,3356119,clearance,"The mean values for young and older subjects for time to peak concentration (2.1 versus 2.5 hours), peak concentrations (465 versus 399 micrograms/mL), elimination half-life (4.2 versus 4.0 hours), clearance (38.8 versus 38.1 mL/min), and distribution volume at steady state (12.5 versus 14.3 L) were not significant.",Glipizide pharmacokinetics in young and elderly volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3356119/),[ml] / [min],38.8,188335,DB01067,Glipizide
,3356119,clearance,"The mean values for young and older subjects for time to peak concentration (2.1 versus 2.5 hours), peak concentrations (465 versus 399 micrograms/mL), elimination half-life (4.2 versus 4.0 hours), clearance (38.8 versus 38.1 mL/min), and distribution volume at steady state (12.5 versus 14.3 L) were not significant.",Glipizide pharmacokinetics in young and elderly volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3356119/),[ml] / [min],38.1,188336,DB01067,Glipizide
,3356119,distribution volume at steady state,"The mean values for young and older subjects for time to peak concentration (2.1 versus 2.5 hours), peak concentrations (465 versus 399 micrograms/mL), elimination half-life (4.2 versus 4.0 hours), clearance (38.8 versus 38.1 mL/min), and distribution volume at steady state (12.5 versus 14.3 L) were not significant.",Glipizide pharmacokinetics in young and elderly volunteers. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3356119/),l,12.5,188337,DB01067,Glipizide
,3356119,distribution volume at steady state,"The mean values for young and older subjects for time to peak concentration (2.1 versus 2.5 hours), peak concentrations (465 versus 399 micrograms/mL), elimination half-life (4.2 versus 4.0 hours), clearance (38.8 versus 38.1 mL/min), and distribution volume at steady state (12.5 versus 14.3 L) were not significant.",Glipizide pharmacokinetics in young and elderly volunteers. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3356119/),l,14.3,188338,DB01067,Glipizide
,15871634,terminal half-life,The estimated terminal half-life of ezetimibe and ezetimibe-glucuronide is approximately 22 hours.,"Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15871634/),h,22,188555,DB01067,Glipizide
,18555754,m,"Following protein precipitation with acetonitrile, 3-n-butylphthalide and glipizide (internal standard, I.S.) were separated using a gradient elution program on a C18 column and detected by mass spectrometry in positive ion mode with the multiple reaction monitoring (MRM) mode using the respective precursor to product ion combinations of m/z 191/145 for 3-n-butylphthalide and m/z 446/321 for glipizide, respectively.",High-performance liquid chromatography for the determination of 3-n-butylphthalide in rat plasma by tandem quadrupole mass spectrometry: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18555754/),,191,189796,DB01067,Glipizide
,18555754,total chromatographic running time,The total chromatographic running time was 2.5 min.,High-performance liquid chromatography for the determination of 3-n-butylphthalide in rat plasma by tandem quadrupole mass spectrometry: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18555754/),min,2.5,189797,DB01067,Glipizide
,7572185,relative bioavailability,The relative bioavailability of the capsule was 109.9% compared with the tablet.,[Pharmacokinetics and bioavailability of glipizide capsules]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7572185/),%,109.9,191762,DB01067,Glipizide
,16509763,peak plasma concentration (C(max)),"The mean peak plasma concentration (C(max)) of the immediate-release formulation (523+/-60 ng/mL) was significantly higher (p<0.05) than those of the three extended-release formulations (403+/-24, 349+/-37 and 426+/-55 ng/mL for GLXL, GTXL and GLPF, respectively).",Bioavailability of immediate- and extended-release formulations of glipizide in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16509763/),[ng] / [ml],523,193391,DB01067,Glipizide
,16509763,peak plasma concentration (C(max)),"The mean peak plasma concentration (C(max)) of the immediate-release formulation (523+/-60 ng/mL) was significantly higher (p<0.05) than those of the three extended-release formulations (403+/-24, 349+/-37 and 426+/-55 ng/mL for GLXL, GTXL and GLPF, respectively).",Bioavailability of immediate- and extended-release formulations of glipizide in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16509763/),[ng] / [ml],403,193392,DB01067,Glipizide
,16509763,peak plasma concentration (C(max)),"The mean peak plasma concentration (C(max)) of the immediate-release formulation (523+/-60 ng/mL) was significantly higher (p<0.05) than those of the three extended-release formulations (403+/-24, 349+/-37 and 426+/-55 ng/mL for GLXL, GTXL and GLPF, respectively).",Bioavailability of immediate- and extended-release formulations of glipizide in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16509763/),[ng] / [ml],349,193393,DB01067,Glipizide
,16509763,peak plasma concentration (C(max)),"The mean peak plasma concentration (C(max)) of the immediate-release formulation (523+/-60 ng/mL) was significantly higher (p<0.05) than those of the three extended-release formulations (403+/-24, 349+/-37 and 426+/-55 ng/mL for GLXL, GTXL and GLPF, respectively).",Bioavailability of immediate- and extended-release formulations of glipizide in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16509763/),[ng] / [ml],426,193394,DB01067,Glipizide
,16509763,time to reach C(max),"Mean time to reach C(max) was 1.83+/-0.3 hours for GL, 4.41+/-1.2 hours for GLXL, 3.21+/-0.8 hours for GTXL and 3.24+/-0.4 hours for GLPF.",Bioavailability of immediate- and extended-release formulations of glipizide in healthy male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16509763/),h,1.83,193395,DB01067,Glipizide
,16509763,time to reach C(max),"Mean time to reach C(max) was 1.83+/-0.3 hours for GL, 4.41+/-1.2 hours for GLXL, 3.21+/-0.8 hours for GTXL and 3.24+/-0.4 hours for GLPF.",Bioavailability of immediate- and extended-release formulations of glipizide in healthy male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16509763/),h,4.41,193396,DB01067,Glipizide
,16509763,time to reach C(max),"Mean time to reach C(max) was 1.83+/-0.3 hours for GL, 4.41+/-1.2 hours for GLXL, 3.21+/-0.8 hours for GTXL and 3.24+/-0.4 hours for GLPF.",Bioavailability of immediate- and extended-release formulations of glipizide in healthy male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16509763/),h,3.21,193397,DB01067,Glipizide
,16509763,time to reach C(max),"Mean time to reach C(max) was 1.83+/-0.3 hours for GL, 4.41+/-1.2 hours for GLXL, 3.21+/-0.8 hours for GTXL and 3.24+/-0.4 hours for GLPF.",Bioavailability of immediate- and extended-release formulations of glipizide in healthy male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16509763/),h,3.24,193398,DB01067,Glipizide
,16509763,area under the plasma concentration-time curve,"The order of magnitude of area under the plasma concentration-time curve was GTXL (5591 ng . h/mL)>GLXL (4,771 ng . h/mL)>GLPF (4,537 ng . h/mL)>GL (1,897 ng . h/mL).",Bioavailability of immediate- and extended-release formulations of glipizide in healthy male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16509763/),[h·ng] / [ml],5591,193399,DB01067,Glipizide
,16509763,area under the plasma concentration-time curve,"The order of magnitude of area under the plasma concentration-time curve was GTXL (5591 ng . h/mL)>GLXL (4,771 ng . h/mL)>GLPF (4,537 ng . h/mL)>GL (1,897 ng . h/mL).",Bioavailability of immediate- and extended-release formulations of glipizide in healthy male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16509763/),[h·ng] / [ml],"4,771",193400,DB01067,Glipizide
,16509763,area under the plasma concentration-time curve,"The order of magnitude of area under the plasma concentration-time curve was GTXL (5591 ng . h/mL)>GLXL (4,771 ng . h/mL)>GLPF (4,537 ng . h/mL)>GL (1,897 ng . h/mL).",Bioavailability of immediate- and extended-release formulations of glipizide in healthy male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16509763/),[h·ng] / [ml],"4,537",193401,DB01067,Glipizide
,16509763,area under the plasma concentration-time curve,"The order of magnitude of area under the plasma concentration-time curve was GTXL (5591 ng . h/mL)>GLXL (4,771 ng . h/mL)>GLPF (4,537 ng . h/mL)>GL (1,897 ng . h/mL).",Bioavailability of immediate- and extended-release formulations of glipizide in healthy male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16509763/),[h·ng] / [ml],"1,897",193402,DB01067,Glipizide
,16509763,mean residence time,"The mean residence time was 3.14+/-0.59 hours for GL, 8.26+/-0.81 hours for GLXL, 9.70+/-2.70 hours for GTXL and 7.87+/-1.93 hours for GLPF.",Bioavailability of immediate- and extended-release formulations of glipizide in healthy male volunteers. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16509763/),h,3.14,193403,DB01067,Glipizide
,16509763,mean residence time,"The mean residence time was 3.14+/-0.59 hours for GL, 8.26+/-0.81 hours for GLXL, 9.70+/-2.70 hours for GTXL and 7.87+/-1.93 hours for GLPF.",Bioavailability of immediate- and extended-release formulations of glipizide in healthy male volunteers. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16509763/),h,8.26,193404,DB01067,Glipizide
,16509763,mean residence time,"The mean residence time was 3.14+/-0.59 hours for GL, 8.26+/-0.81 hours for GLXL, 9.70+/-2.70 hours for GTXL and 7.87+/-1.93 hours for GLPF.",Bioavailability of immediate- and extended-release formulations of glipizide in healthy male volunteers. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16509763/),h,9.70,193405,DB01067,Glipizide
,16509763,mean residence time,"The mean residence time was 3.14+/-0.59 hours for GL, 8.26+/-0.81 hours for GLXL, 9.70+/-2.70 hours for GTXL and 7.87+/-1.93 hours for GLPF.",Bioavailability of immediate- and extended-release formulations of glipizide in healthy male volunteers. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16509763/),h,7.87,193406,DB01067,Glipizide
,22821721,flow rate,"The analytes were extracted by using liquid-liquid extraction procedure and separated on a reverse phase C18 column (50 mm×4.6 mm i. d., 5 µ) using acetonitrile: 2 mM ammonium acetate buffer, pH 3.2 (90:10, v/v) as mobile phase at a flow rate 0.4 mL/min in an isocratic mode.","Liquid chromatography - tandem mass spectrometry for the simultaneous quantitation of glipizide, cilostazol and its active metabolite 3, 4-dehydro-cilostazol in rat plasma: application for a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22821721/),[ml] / [min],0.4,199837,DB01067,Glipizide
>,22821721,recoveries,The recoveries from spiked control samples were>76% for all analytes and internal standard.,"Liquid chromatography - tandem mass spectrometry for the simultaneous quantitation of glipizide, cilostazol and its active metabolite 3, 4-dehydro-cilostazol in rat plasma: application for a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22821721/),%,76,199838,DB01067,Glipizide
,7027750,duration,"The duration of the immediate effects of glipizide on B-G, S-IRI and S-IRI/B-G was 9, 4.5 and 6.5 hours, respectively.",The antidiabetic effect and pharmacokinetic properties of glipizide. Comparison of a single dose with divided dose regime. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7027750/),h,9,200876,DB01067,Glipizide
,7027750,duration,"The duration of the immediate effects of glipizide on B-G, S-IRI and S-IRI/B-G was 9, 4.5 and 6.5 hours, respectively.",The antidiabetic effect and pharmacokinetic properties of glipizide. Comparison of a single dose with divided dose regime. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7027750/),h,4.5,200877,DB01067,Glipizide
,7027750,duration,"The duration of the immediate effects of glipizide on B-G, S-IRI and S-IRI/B-G was 9, 4.5 and 6.5 hours, respectively.",The antidiabetic effect and pharmacokinetic properties of glipizide. Comparison of a single dose with divided dose regime. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7027750/),h,6.5,200878,DB01067,Glipizide
,7027750,apparent half-life,"The mean apparent half-life of glipizide was 4.1 hours, the mean distribution volume 0.13 l/kg and the mean plasma clearance 0.023 l/kg x h.",The antidiabetic effect and pharmacokinetic properties of glipizide. Comparison of a single dose with divided dose regime. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7027750/),h,4.1,200879,DB01067,Glipizide
,7027750,distribution volume,"The mean apparent half-life of glipizide was 4.1 hours, the mean distribution volume 0.13 l/kg and the mean plasma clearance 0.023 l/kg x h.",The antidiabetic effect and pharmacokinetic properties of glipizide. Comparison of a single dose with divided dose regime. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7027750/),[l] / [kg],0.13,200880,DB01067,Glipizide
,7027750,plasma clearance,"The mean apparent half-life of glipizide was 4.1 hours, the mean distribution volume 0.13 l/kg and the mean plasma clearance 0.023 l/kg x h.",The antidiabetic effect and pharmacokinetic properties of glipizide. Comparison of a single dose with divided dose regime. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7027750/),[l] / [h·kg],0.023,200881,DB01067,Glipizide
,7027750,B-G,"There were no significant differences between the single and divided dose regimes as regards B-G, S-IRI and S-IRI/B-G, although the mean B-G for the 12-hour period was somewhat lower after the former than after the latter (7.0 against 8.7 mmol/l).",The antidiabetic effect and pharmacokinetic properties of glipizide. Comparison of a single dose with divided dose regime. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7027750/),[mM] / [l],7.0,200882,DB01067,Glipizide
,7027750,B-G,"There were no significant differences between the single and divided dose regimes as regards B-G, S-IRI and S-IRI/B-G, although the mean B-G for the 12-hour period was somewhat lower after the former than after the latter (7.0 against 8.7 mmol/l).",The antidiabetic effect and pharmacokinetic properties of glipizide. Comparison of a single dose with divided dose regime. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7027750/),[mM] / [l],8.7,200883,DB01067,Glipizide
over,22425386,extraction recovery,The extraction recovery of WJ-38 from rat plasma was over 66.0%.,"Development and validation of a rapid high-performance liquid chromatography-tandem mass spectrometry method for the determination of WJ-38, a novel aldose reductase inhibitor, in rat plasma and its application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22425386/),%,66.0,206742,DB01067,Glipizide
,32454724,zeta potential,"The optimized GN1 had particle size 242.60±4.20 nm, PDI 0.171±0.014, and zeta potential -21.41±0.462 mV.",Palmitic Acid-Pluronic F127-Palmitic Acid Pentablock Copolymer as a Novel Nanocarrier for Oral Delivery of Glipizide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32454724/),mv,21.41,210391,DB01067,Glipizide
,22626894,flow rate,"The analysis was performed on a Diamonsil® C₁₈(2) column (150 mm × 4.6 mm, 5 μm) with the mobile phase consisting of 0.1% formic acid-acetonitrile (57:43, v/v, pH=3.0) at a flow rate of 0.8 mL min⁻¹.",Determination of the active metabolite of moguisteine in human plasma and urine by LC-ESI-MS method and its application in pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22626894/),min⁻¹·ml,0.8,226116,DB01067,Glipizide
,22626894,m/z,The pseudo-molecular ions [M+H]+ (m/z 312.2 for M1 and 446.3 for glipizide) were selected as the target ions for quantification in the selected ion monitoring (SIM) mode.,Determination of the active metabolite of moguisteine in human plasma and urine by LC-ESI-MS method and its application in pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22626894/),,312.2,226117,DB01067,Glipizide
,22626894,m/z,The pseudo-molecular ions [M+H]+ (m/z 312.2 for M1 and 446.3 for glipizide) were selected as the target ions for quantification in the selected ion monitoring (SIM) mode.,Determination of the active metabolite of moguisteine in human plasma and urine by LC-ESI-MS method and its application in pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22626894/),,446.3,226118,DB01067,Glipizide
over,22626894,extraction recovery,The extraction recovery in plasma was over 90%.,Determination of the active metabolite of moguisteine in human plasma and urine by LC-ESI-MS method and its application in pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22626894/),%,90,226119,DB01067,Glipizide
,8848822,Tmax,No statistically significant differences in the SD pharmacokinetic parameters (Tmax = 3.1 +/- 1.2 vs.,The effects of obesity on the pharmacokinetics and pharmacodynamics of glipizide in patients with non-insulin-dependent diabetes mellitus. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8848822/),,3.1,233180,DB01067,Glipizide
,8848822,Cmax,2.8 +/- 1.6 h; Cmax = 332.5 +/- 92.5 vs.,The effects of obesity on the pharmacokinetics and pharmacodynamics of glipizide in patients with non-insulin-dependent diabetes mellitus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8848822/),,332.5,233181,DB01067,Glipizide
,8848822,area under the curve extrapolated to infinity (AUCI),"420.8 +/- 142 g/L; area under the curve extrapolated to infinity (AUCI) = 2,598.3 +/- 1,148 vs. 3,138.9 +/- 1,847 g/h/L; oral clearance/bioavailability (CL/F), 2.3 +/- 1.0 vs.",The effects of obesity on the pharmacokinetics and pharmacodynamics of glipizide in patients with non-insulin-dependent diabetes mellitus. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8848822/),[g] / [h·l],"2,598.3",233182,DB01067,Glipizide
,8848822,area under the curve extrapolated to infinity (AUCI),"420.8 +/- 142 g/L; area under the curve extrapolated to infinity (AUCI) = 2,598.3 +/- 1,148 vs. 3,138.9 +/- 1,847 g/h/L; oral clearance/bioavailability (CL/F), 2.3 +/- 1.0 vs.",The effects of obesity on the pharmacokinetics and pharmacodynamics of glipizide in patients with non-insulin-dependent diabetes mellitus. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8848822/),[g] / [h·l],"3,138.9",233183,DB01067,Glipizide
,8848822,oral clearance/bioavailability (CL/F),"420.8 +/- 142 g/L; area under the curve extrapolated to infinity (AUCI) = 2,598.3 +/- 1,148 vs. 3,138.9 +/- 1,847 g/h/L; oral clearance/bioavailability (CL/F), 2.3 +/- 1.0 vs.",The effects of obesity on the pharmacokinetics and pharmacodynamics of glipizide in patients with non-insulin-dependent diabetes mellitus. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8848822/),,2.3,233184,DB01067,Glipizide
,8848822,volume of distribution/bioavailability (V/F),"2.0 +/- 1.0 L/h; volume of distribution/bioavailability (V/F), 19.5 +/- 4.4 vs.",The effects of obesity on the pharmacokinetics and pharmacodynamics of glipizide in patients with non-insulin-dependent diabetes mellitus. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8848822/),,19.5,233185,DB01067,Glipizide
,8848822,t1/2,17.2 +/- 4.3 L; t1/2 = 5.0 +/- 2.3 vs.,The effects of obesity on the pharmacokinetics and pharmacodynamics of glipizide in patients with non-insulin-dependent diabetes mellitus. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8848822/),,5.0,233186,DB01067,Glipizide
,8848822,AUC0-->4.glucose,"No differences in glucose responses to Sustacal challenge at baseline, SD, and CD (AUC0-->4.glucose:baseline, 52.3 +/- 18.0 vs. 44.9 +/- 9.8; SD, 50.4 +/- 20.9 vs. 36.1 +/- 11.0; CD, 37.8 +/- 10.7 vs.",The effects of obesity on the pharmacokinetics and pharmacodynamics of glipizide in patients with non-insulin-dependent diabetes mellitus. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8848822/),,52.3,233187,DB01067,Glipizide
,8848822,AUC0-->4.glucose,"No differences in glucose responses to Sustacal challenge at baseline, SD, and CD (AUC0-->4.glucose:baseline, 52.3 +/- 18.0 vs. 44.9 +/- 9.8; SD, 50.4 +/- 20.9 vs. 36.1 +/- 11.0; CD, 37.8 +/- 10.7 vs.",The effects of obesity on the pharmacokinetics and pharmacodynamics of glipizide in patients with non-insulin-dependent diabetes mellitus. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8848822/),,44.9,233188,DB01067,Glipizide
,8848822,AUC0-->4.glucose,"No differences in glucose responses to Sustacal challenge at baseline, SD, and CD (AUC0-->4.glucose:baseline, 52.3 +/- 18.0 vs. 44.9 +/- 9.8; SD, 50.4 +/- 20.9 vs. 36.1 +/- 11.0; CD, 37.8 +/- 10.7 vs.",The effects of obesity on the pharmacokinetics and pharmacodynamics of glipizide in patients with non-insulin-dependent diabetes mellitus. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8848822/),,50.4,233189,DB01067,Glipizide
,8848822,AUC0-->4.glucose,"No differences in glucose responses to Sustacal challenge at baseline, SD, and CD (AUC0-->4.glucose:baseline, 52.3 +/- 18.0 vs. 44.9 +/- 9.8; SD, 50.4 +/- 20.9 vs. 36.1 +/- 11.0; CD, 37.8 +/- 10.7 vs.",The effects of obesity on the pharmacokinetics and pharmacodynamics of glipizide in patients with non-insulin-dependent diabetes mellitus. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8848822/),,36.1,233190,DB01067,Glipizide
,8848822,AUC0-->4.glucose,"No differences in glucose responses to Sustacal challenge at baseline, SD, and CD (AUC0-->4.glucose:baseline, 52.3 +/- 18.0 vs. 44.9 +/- 9.8; SD, 50.4 +/- 20.9 vs. 36.1 +/- 11.0; CD, 37.8 +/- 10.7 vs.",The effects of obesity on the pharmacokinetics and pharmacodynamics of glipizide in patients with non-insulin-dependent diabetes mellitus. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8848822/),,37.8,233191,DB01067,Glipizide
,8848822,C-peptide,"However, obese subjects exhibited higher fasting insulin (114.0 +/- 69 vs. 68.8 +/- 52 pM) at week 12 evaluation and C-peptide concentrations (0.83 +/- 0.2 vs. 0.63 +/- 0.2 nM) after SD as compared to the nonobese group.",The effects of obesity on the pharmacokinetics and pharmacodynamics of glipizide in patients with non-insulin-dependent diabetes mellitus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8848822/),nM,0.83,233192,DB01067,Glipizide
,8848822,C-peptide,"However, obese subjects exhibited higher fasting insulin (114.0 +/- 69 vs. 68.8 +/- 52 pM) at week 12 evaluation and C-peptide concentrations (0.83 +/- 0.2 vs. 0.63 +/- 0.2 nM) after SD as compared to the nonobese group.",The effects of obesity on the pharmacokinetics and pharmacodynamics of glipizide in patients with non-insulin-dependent diabetes mellitus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8848822/),nM,0.63,233193,DB01067,Glipizide
,7836551,area under the curve (AUC),"Glipizide area under the curve (AUC), clearance, and half life for treatment and control phases were 5758 +/- 1874 versus 5176 +/- 1505 micrograms/L/hour (P = .21), 0.41 +/- 0.15 versus 0.45 +/- 0.14 mL/min/kg (P = .27), and 5.13 +/- 2.10 versus 3.95 +/- 1.37 hours (P = .04), respectively.",Lack of interaction between glipizide and co-trimoxazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7836551/),[μg] / [h·l],5758,238077,DB01067,Glipizide
,7836551,clearance,"Glipizide area under the curve (AUC), clearance, and half life for treatment and control phases were 5758 +/- 1874 versus 5176 +/- 1505 micrograms/L/hour (P = .21), 0.41 +/- 0.15 versus 0.45 +/- 0.14 mL/min/kg (P = .27), and 5.13 +/- 2.10 versus 3.95 +/- 1.37 hours (P = .04), respectively.",Lack of interaction between glipizide and co-trimoxazole. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7836551/),[μg] / [h·l],5176,238078,DB01067,Glipizide
,7836551,clearance,"Glipizide area under the curve (AUC), clearance, and half life for treatment and control phases were 5758 +/- 1874 versus 5176 +/- 1505 micrograms/L/hour (P = .21), 0.41 +/- 0.15 versus 0.45 +/- 0.14 mL/min/kg (P = .27), and 5.13 +/- 2.10 versus 3.95 +/- 1.37 hours (P = .04), respectively.",Lack of interaction between glipizide and co-trimoxazole. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7836551/),[ml] / [kg·min],0.41,238079,DB01067,Glipizide
,7836551,half life,"Glipizide area under the curve (AUC), clearance, and half life for treatment and control phases were 5758 +/- 1874 versus 5176 +/- 1505 micrograms/L/hour (P = .21), 0.41 +/- 0.15 versus 0.45 +/- 0.14 mL/min/kg (P = .27), and 5.13 +/- 2.10 versus 3.95 +/- 1.37 hours (P = .04), respectively.",Lack of interaction between glipizide and co-trimoxazole. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7836551/),[ml] / [kg·min],0.45,238080,DB01067,Glipizide
,7836551,half life,"Glipizide area under the curve (AUC), clearance, and half life for treatment and control phases were 5758 +/- 1874 versus 5176 +/- 1505 micrograms/L/hour (P = .21), 0.41 +/- 0.15 versus 0.45 +/- 0.14 mL/min/kg (P = .27), and 5.13 +/- 2.10 versus 3.95 +/- 1.37 hours (P = .04), respectively.",Lack of interaction between glipizide and co-trimoxazole. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7836551/),h,5.13,238081,DB01067,Glipizide
,7836551,half life,"Glipizide area under the curve (AUC), clearance, and half life for treatment and control phases were 5758 +/- 1874 versus 5176 +/- 1505 micrograms/L/hour (P = .21), 0.41 +/- 0.15 versus 0.45 +/- 0.14 mL/min/kg (P = .27), and 5.13 +/- 2.10 versus 3.95 +/- 1.37 hours (P = .04), respectively.",Lack of interaction between glipizide and co-trimoxazole. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7836551/),h,3.95,238082,DB01067,Glipizide
,7836551,Twenty-four-hour,"Twenty-four-hour glucose AUCs for treatment and control phases were 112.24 +/- 8.76 versus 114.86 +/- 11.98 mmol/L/hour (P = .55), respectively.",Lack of interaction between glipizide and co-trimoxazole. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7836551/),[mM] / [h·l],112.24,238083,DB01067,Glipizide
,7836551,glucose AUCs,"Twenty-four-hour glucose AUCs for treatment and control phases were 112.24 +/- 8.76 versus 114.86 +/- 11.98 mmol/L/hour (P = .55), respectively.",Lack of interaction between glipizide and co-trimoxazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7836551/),[mM] / [h·l],112.24,238084,DB01067,Glipizide
,7836551,glucose AUCs,"Twenty-four-hour glucose AUCs for treatment and control phases were 112.24 +/- 8.76 versus 114.86 +/- 11.98 mmol/L/hour (P = .55), respectively.",Lack of interaction between glipizide and co-trimoxazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7836551/),[mM] / [h·l],114.86,238085,DB01067,Glipizide
,16111851,LOQ (s/n,The LOQ (s/n = 10) of the method was 10 ng/ml.,A selective HPLC method for the determination of indapamide in human whole blood: application to a bioequivalence study in Chinese volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16111851/),[ng] / [ml],10,254340,DB01067,Glipizide
,16111851,C(max),"The mean values of major pharmacokinetic parameters of C(max), AUC(0-48), AUC(0-infinity), T(max), and t(1/2) of indapamide in healthy male Chinese volunteers after po a single 5 mg dose for the test product were 331.0 +/- 39.2 ng/ml, 6,193.7+/-873.5 ng h/ml, 7311.8+/-1,232.3 ng h/ml, 3.2+/-0.9h, and 17.3+/-2.8 h, respectively.",A selective HPLC method for the determination of indapamide in human whole blood: application to a bioequivalence study in Chinese volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16111851/),[ng] / [ml],331.0,254341,DB01067,Glipizide
,16111851,AUC(0-48),"The mean values of major pharmacokinetic parameters of C(max), AUC(0-48), AUC(0-infinity), T(max), and t(1/2) of indapamide in healthy male Chinese volunteers after po a single 5 mg dose for the test product were 331.0 +/- 39.2 ng/ml, 6,193.7+/-873.5 ng h/ml, 7311.8+/-1,232.3 ng h/ml, 3.2+/-0.9h, and 17.3+/-2.8 h, respectively.",A selective HPLC method for the determination of indapamide in human whole blood: application to a bioequivalence study in Chinese volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16111851/),[h·ng] / [ml],"6,193.7",254342,DB01067,Glipizide
,16111851,AUC(0-48),"The mean values of major pharmacokinetic parameters of C(max), AUC(0-48), AUC(0-infinity), T(max), and t(1/2) of indapamide in healthy male Chinese volunteers after po a single 5 mg dose for the test product were 331.0 +/- 39.2 ng/ml, 6,193.7+/-873.5 ng h/ml, 7311.8+/-1,232.3 ng h/ml, 3.2+/-0.9h, and 17.3+/-2.8 h, respectively.",A selective HPLC method for the determination of indapamide in human whole blood: application to a bioequivalence study in Chinese volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16111851/),[h·ng] / [ml],7311.8,254343,DB01067,Glipizide
,16111851,AUC(0-infinity),"The mean values of major pharmacokinetic parameters of C(max), AUC(0-48), AUC(0-infinity), T(max), and t(1/2) of indapamide in healthy male Chinese volunteers after po a single 5 mg dose for the test product were 331.0 +/- 39.2 ng/ml, 6,193.7+/-873.5 ng h/ml, 7311.8+/-1,232.3 ng h/ml, 3.2+/-0.9h, and 17.3+/-2.8 h, respectively.",A selective HPLC method for the determination of indapamide in human whole blood: application to a bioequivalence study in Chinese volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16111851/),[h·ng] / [ml],"6,193.7",254344,DB01067,Glipizide
,16111851,AUC(0-infinity),"The mean values of major pharmacokinetic parameters of C(max), AUC(0-48), AUC(0-infinity), T(max), and t(1/2) of indapamide in healthy male Chinese volunteers after po a single 5 mg dose for the test product were 331.0 +/- 39.2 ng/ml, 6,193.7+/-873.5 ng h/ml, 7311.8+/-1,232.3 ng h/ml, 3.2+/-0.9h, and 17.3+/-2.8 h, respectively.",A selective HPLC method for the determination of indapamide in human whole blood: application to a bioequivalence study in Chinese volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16111851/),[h·ng] / [ml],7311.8,254345,DB01067,Glipizide
,16111851,T(max),"The mean values of major pharmacokinetic parameters of C(max), AUC(0-48), AUC(0-infinity), T(max), and t(1/2) of indapamide in healthy male Chinese volunteers after po a single 5 mg dose for the test product were 331.0 +/- 39.2 ng/ml, 6,193.7+/-873.5 ng h/ml, 7311.8+/-1,232.3 ng h/ml, 3.2+/-0.9h, and 17.3+/-2.8 h, respectively.",A selective HPLC method for the determination of indapamide in human whole blood: application to a bioequivalence study in Chinese volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16111851/),[h·ng] / [ml],"6,193.7",254346,DB01067,Glipizide
,16111851,T(max),"The mean values of major pharmacokinetic parameters of C(max), AUC(0-48), AUC(0-infinity), T(max), and t(1/2) of indapamide in healthy male Chinese volunteers after po a single 5 mg dose for the test product were 331.0 +/- 39.2 ng/ml, 6,193.7+/-873.5 ng h/ml, 7311.8+/-1,232.3 ng h/ml, 3.2+/-0.9h, and 17.3+/-2.8 h, respectively.",A selective HPLC method for the determination of indapamide in human whole blood: application to a bioequivalence study in Chinese volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16111851/),[h·ng] / [ml],7311.8,254347,DB01067,Glipizide
,16111851,t(1/2),"The mean values of major pharmacokinetic parameters of C(max), AUC(0-48), AUC(0-infinity), T(max), and t(1/2) of indapamide in healthy male Chinese volunteers after po a single 5 mg dose for the test product were 331.0 +/- 39.2 ng/ml, 6,193.7+/-873.5 ng h/ml, 7311.8+/-1,232.3 ng h/ml, 3.2+/-0.9h, and 17.3+/-2.8 h, respectively.",A selective HPLC method for the determination of indapamide in human whole blood: application to a bioequivalence study in Chinese volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16111851/),h,3.2,254348,DB01067,Glipizide
,16111851,t(1/2),"The mean values of major pharmacokinetic parameters of C(max), AUC(0-48), AUC(0-infinity), T(max), and t(1/2) of indapamide in healthy male Chinese volunteers after po a single 5 mg dose for the test product were 331.0 +/- 39.2 ng/ml, 6,193.7+/-873.5 ng h/ml, 7311.8+/-1,232.3 ng h/ml, 3.2+/-0.9h, and 17.3+/-2.8 h, respectively.",A selective HPLC method for the determination of indapamide in human whole blood: application to a bioequivalence study in Chinese volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16111851/),h,17.3,254349,DB01067,Glipizide
,23370433,"f2""","It was found that the formulation presented a well zero-order behavior at the weight ratio of drug 11:14 (core:layer) and the combination of HPC-L (8.0 mPa s) and HPC-M (350 mPa s) (8:9), with the ""f2"" of 66.90.",Compression-coated tablets of glipizide using hydroxypropylcellulose for zero-order release: in vitro and in vivo evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23370433/),,66.90,259707,DB01067,Glipizide
,23370433,AUC0-∞,"The parameter AUC0-∞ of the compression coated tablets and the market tablets were 37,255.93±1474.08 h ng/ml and 43265.40±1015.28 h ng/ml, while the relative bioavailability was 87.66±1.56%.",Compression-coated tablets of glipizide using hydroxypropylcellulose for zero-order release: in vitro and in vivo evaluation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23370433/),[h·ng] / [ml],"37,255.93",259708,DB01067,Glipizide
,23370433,AUC0-∞,"The parameter AUC0-∞ of the compression coated tablets and the market tablets were 37,255.93±1474.08 h ng/ml and 43265.40±1015.28 h ng/ml, while the relative bioavailability was 87.66±1.56%.",Compression-coated tablets of glipizide using hydroxypropylcellulose for zero-order release: in vitro and in vivo evaluation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23370433/),[h·ng] / [ml],43265.40,259709,DB01067,Glipizide
,23370433,relative bioavailability,"The parameter AUC0-∞ of the compression coated tablets and the market tablets were 37,255.93±1474.08 h ng/ml and 43265.40±1015.28 h ng/ml, while the relative bioavailability was 87.66±1.56%.",Compression-coated tablets of glipizide using hydroxypropylcellulose for zero-order release: in vitro and in vivo evaluation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23370433/),%,87.66,259710,DB01067,Glipizide
,6754633,elimination half-life,"The mean elimination half-life was 4.7 +/- 0.4 h, Vd 17.0 +/- 2.6 l, and the calculated total clearance 41.6 +/- 4.3 ml/min (mean +/- s.e.m.).",Glipizide pharmacokinetics and response in diabetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6754633/),h,4.7,267700,DB01067,Glipizide
,6754633,Vd,"The mean elimination half-life was 4.7 +/- 0.4 h, Vd 17.0 +/- 2.6 l, and the calculated total clearance 41.6 +/- 4.3 ml/min (mean +/- s.e.m.).",Glipizide pharmacokinetics and response in diabetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6754633/),l,17.0,267701,DB01067,Glipizide
,6754633,total clearance,"The mean elimination half-life was 4.7 +/- 0.4 h, Vd 17.0 +/- 2.6 l, and the calculated total clearance 41.6 +/- 4.3 ml/min (mean +/- s.e.m.).",Glipizide pharmacokinetics and response in diabetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6754633/),[ml] / [min],41.6,267702,DB01067,Glipizide
